| Name | Title | Contact Details |
|---|---|---|
Kenny Wong |
Director of IT | Profile |
Denodo is the leader in data management – providing unmatched performance, unified access to the broadest range of enterprise, big data, cloud and unstructured sources, and the most agile data services provisioning and governance – at less than half the cost of traditional data integration. Denodo`s customers have gained significant business agility and ROI by creating a unified virtual data layer that serves strategic enterprise-wide information needs for agile BI, big data analytics, web and cloud integration, single-view applications, and SOA data services across every major industry. Denodo Platform offers the broadest access to structured and unstructured data residing in enterprise, big data, and cloud sources, in both batch and real-time, exceeding the performance needs of data-intensive organizations for both analytical and operational use cases, delivered in a much shorter timeframe than traditional data integration tools. The Denodo Platform drives agility, faster time to market, increased customer engagement from single view of customer and operational efficiencies from real-time business intelligence and self-serviceability. Founded in 1999, Denodo is privately held, with headquarters in Palo Alto and 25 offices in 20 countries across NA, EMEA and APAC.
Student loans can be confusing and overwhelming. Chipper has reimagined student loans to help you better understand, manage, and chip away your debt.
ObvioHealth is a global digital health organization providing real-world digital clinical trials that deliver better data. Our mobile clinical study application allows for site-less trial design, allowing subjects to use their smartphones to participate in remote monitoring clinical trials from the comfort of their homes. For studies designed to include site visits, our application allows for continuous data collection in between visits to the clinic.
Rexnord Corporation is a Milwaukee, Wisconsin-based company listed on the New York Stock Exchange.
Since the Company's inception in 1999, scientists and engineers at AutoGenomics have endeavored to create automated technologies that simplify the complex test processes inherent in genetic analysis within a format that is user friendly and increases productivity in the clinical laboratory. The INFINITI® system is designed specifically for processing AutoGenomics' unique proprietary BioFilmChip® microarrays that can be multiplexed and configured with hundreds of biomarkers to assess disease signatures from a single sample specimen. The INFINITI system provides clinical laboratories with significant improvements in laboratory productivity, workflow and cost per reportable result. Corporate Overview